Go Pro
NASDAQ:ABVC

ABVC BioPharma Q1 2026 Earnings Report

ABVC BioPharma logo
$1.06 +0.02 (+1.92%)
Closing price 04:00 PM Eastern
Extended Trading
$1.06 -0.01 (-0.47%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ABVC BioPharma EPS Results

Actual EPS
-$0.06
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

ABVC BioPharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ABVC BioPharma Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Monday, May 18, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

ABVC BioPharma's Q3 2026 earnings is estimated for Monday, November 16, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

ABVC BioPharma Earnings Headlines

ABVC BioPharma (NASDAQ:ABVC) and PainReform (NASDAQ:PRFX) Financial Comparison
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
ABVC BioPharma Delays Quarterly SEC Filing
ABVC BioPharma Reports 2025 Form 10-K
ABVC BioPharma Provides Corporate and Structural Update
See More ABVC BioPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ABVC BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ABVC BioPharma and other key companies, straight to your email.

About ABVC BioPharma

ABVC BioPharma (NASDAQ:ABVC) is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders and certain cancers. The company’s approach combines internally developed drug candidates with technologies licensed from academic and research institutions.

Its development programs have included candidates for major depressive disorder, attention-deficit/hyperactivity disorder and other neurological conditions, as well as investigational treatments in oncology. ABVC has also pursued companion diagnostic and biomarker-related technologies intended to support drug development and patient selection.

Headquartered in Fremont, California, ABVC BioPharma has worked with research and clinical partners in the United States and internationally, including institutions in Taiwan. The company was formerly known as American BriVision (Holding) Corp. and changed its name to ABVC BioPharma, Inc. as it expanded its focus on biotechnology development programs.

View ABVC BioPharma Profile